Oruka Therapeutics, INC Form 4 insider transactions

Janus Henderson Group PLC, through its fund, continues to increase its holdings in ARCA biopharma, Inc., with multiple purchases of common stock.

Oruka Therapeutics amends its subscription agreement with investors, issuing warrants to employees and service providers, in preparation for its merger with ARCA biopharma.

ARCA Biopharma is set to merge with Oruka Therapeutics, a company focused on developing best-in-class therapies for psoriasis and other inflammatory skin diseases, with a concurrent $275 million PIPE financing.

ARCA biopharma reported its first quarter 2024 financial results, announced a merger agreement with Oruka Therapeutics, and appointed Thomas Keuer as President.

ARCA biopharma and Oruka Therapeutics have announced a merger agreement to form a company focused on developing novel biologics for chronic skin diseases, supported by a $275 million pre-closing private financing.